Nuvectis Pharma Inc NVCT:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:02 PM EDT
8.14UNCH (UNCH)
Volume
1,327
Close
8.14quote price arrow up+1.38 (+20.41%)
Volume
104,960
52 week range
5.92 - 18.65
Loading...
  • Open6.93
  • Day High8.29
  • Day Low6.90
  • Prev Close6.76
  • 52 Week High18.65
  • 52 Week High Date06/14/23
  • 52 Week Low5.92
  • 52 Week Low Date04/30/24

Key Stats

  • Market Cap149.538M
  • Shares Out18.37M
  • 10 Day Average Volume0.07M
  • Dividend-
  • Dividend Yield-
  • Beta0.44
  • YTD % Change-2.55

KEY STATS

  • Open6.93
  • Day High8.29
  • Day Low6.90
  • Prev Close6.76
  • 52 Week High18.65
  • 52 Week High Date06/14/23
  • 52 Week Low5.92
  • 52 Week Low Date04/30/24
  • Market Cap149.538M
  • Shares Out18.37M
  • 10 Day Average Volume0.07M
  • Dividend-
  • Dividend Yield-
  • Beta0.44
  • YTD % Change-2.55

RATIOS/PROFITABILITY

  • EPS (TTM)-1.42
  • P/E (TTM)-5.71
  • Fwd P/E (NTM)-5.32
  • EBITDA (TTM)-22.897M
  • ROE (TTM)-168.51%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/06/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Nuvectis Pharma Inc

 

Profile

MORE
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is developing two drug candidates: NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator, which is in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an investigator-sponsored clinical trial for the...
Ron Bentsur
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Michael Carson
Vice President - Finance
Address
1 Bridge Plaza, Suite 275
Fort Lee, NJ
07024
United States

Top Peers

SYMBOLLASTCHG%CHG
IMUX
Immunic Inc
1.37+0.04+3.01%
VOR
Vor Biopharma Inc
1.80+0.04+2.27%
GLYC
GlycoMimetics Inc
1.83+0.11+6.40%
RZLT
Rezolute Inc
3.31+0.34+11.45%
LPTX
Leap Therapeutics Inc
3.19+0.02+0.63%